Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies

被引:99
作者
Kawamoto, Atsuhiko
Asahara, Takayuki
机构
[1] Inst Bio Res & Innovat, Vasc Regenerat Res Grp, Chuo Ku, Kobe, Hyogo 6500047, Japan
[2] RIKEN, Ctr Dev Biol, Lab Stem Cell Translat Res, Kobe, Hyogo, Japan
[3] Tokai Univ, Sch Med, Dept Regenerat Med Sci, Isehara, Kanagawa 25911, Japan
关键词
endothelial progenitor cell; regeneration; vasculogenesis;
D O I
10.1002/ccd.21292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The field of cell-based transplantation has expanded considerably and is poised to become an established cardiovascular therapy in the near future. In this review, we will focus on endothelial progenitor cells (EPCs), which are immature cells capable of differentiating into mature endothelial cells. EPCs share many surface marker antigens such as CD34, AC133, Flk-1, etc. with hematopoietic stem cells (HSCs) and the major source of EPCs as well as HSCs is the bone marrow (BM). BM-derived EPCs are mobilized into peripheral blood and recruited to the foci of pathophysiological neovascularization and reendothelialization, thereby contributing to vascular regeneration. Severe EPC dysfunction is an indicator of poor prognosis and severe endothelial dysfunction. Indeed, number of circulating EPCs and their migratory activity are reduced in patients with diabetes, coronary artery disease (CAD), or subjects with multiple coronary risk factors. Effective neovascularization induced by EPC transplantation for hindlimb, myocardial, and cerebral ischemia has been demonstrated in many preclinical studies, and early clinical trials of EPC transplantation in chronic and acute CAD indicate safety and feasibility of myocardial cell-based therapies. For therapeutic reendothelialization in patients undergoing percutaneous coronary intervention, CD34 antibody-coated stents have been used clinically to capture circulating EPCs at the injury sites and enhance reendothelialization and safety of stents. Further development in cell processing technology for efficient isolation, expansion, mobilization, recruitment, and transplantation of EPCs into target tissues are under-way and expected to be tested in clinical trials in the near future. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:477 / 484
页数:8
相关论文
共 49 条
[1]   Endothelial progenitor cell capture by stents coated with antibody against CD34 - The HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry [J].
Aoki, J ;
Serruys, PW ;
van Beusekom, H ;
Ong, ATL ;
McFadden, EP ;
Sianos, G ;
van der Giessen, WJ ;
Regar, E ;
de Feyter, PJ ;
Davis, HR ;
Rowland, S ;
Kutryk, MJB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (10) :1574-1579
[2]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[3]   Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization [J].
Asahara, T ;
Masuda, H ;
Takahashi, T ;
Kalka, C ;
Pastore, C ;
Silver, M ;
Kearne, M ;
Magner, M ;
Isner, JM .
CIRCULATION RESEARCH, 1999, 85 (03) :221-228
[4]   VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].
Asahara, T ;
Takahashi, T ;
Masuda, H ;
Kalka, C ;
Chen, DH ;
Iwaguro, H ;
Inai, Y ;
Silver, M ;
Isner, JM .
EMBO JOURNAL, 1999, 18 (14) :3964-3972
[5]   Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction -: (TOPCARE-AMI) [J].
Assmus, B ;
Schächinger, V ;
Teupe, C ;
Britten, M ;
Lehmann, R ;
Döbert, N ;
Grünwald, F ;
Aicher, A ;
Urbich, C ;
Martin, H ;
Hoelzer, D ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2002, 106 (24) :3009-3017
[6]   Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction - Feasibility and safety [J].
Bartunek, J ;
Vanderheyden, M ;
Vandekerckhove, B ;
Mansour, S ;
De Bruyne, B ;
De Bondt, P ;
Van Haute, I ;
Lootens, N ;
Heyndrickx, G ;
Wijns, W .
CIRCULATION, 2005, 112 (09) :I178-I183
[7]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[8]   Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation [J].
Crosby, JR ;
Kaminski, WE ;
Schatteman, G ;
Martin, PJ ;
Raines, EW ;
Seifert, RA ;
Bowen-Pope, DF .
CIRCULATION RESEARCH, 2000, 87 (09) :728-730
[9]   HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway [J].
Dimmeler, S ;
Aicher, A ;
Vasa, M ;
Mildner-Rihm, C ;
Adler, K ;
Tiemann, M ;
Rütten, H ;
Fichtlscherer, S ;
Martin, H ;
Zeiher, AM .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (03) :391-397
[10]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442